![[feed]](/style/images/feed-icon-14x14.png){kind=icon}
Tools
Tools
Preview |
PDF (Original Article)
- Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
500kB |
| Item Type: | Letter |
|---|---|
| Title: | Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group |
| Creators Name: | Damaschin, C., Goergen, H., Kreissl, S., Plütschow, A., Breywisch, F., Mathas, S., Meissner, J., Sökler, M., Topp, M.S., Vucinic, V., Zimmermann, A., von Tresckow, B., Fuchs, M., Engert, A., Borchmann, P. and Eichenauer, D.A. |
| Keywords: | Antineoplastic Combined Chemotherapy Protocols, Bleomycin, Brentuximab Vedotin, Cyclophosphamide, Etoposide, Follow-Up Studies, Hodgkin Disease, Local Neoplasm Recurrence, Phase II as Topic Clinical Trials, Prognosis, Randomized Controlled Trials as Topic, Second Primary Neoplasms, Survival Rate, Vincristine |
| Source: | Leukemia |
| ISSN: | 0887-6924 |
| Publisher: | Nature Publishing Group |
| Volume: | 36 |
| Number: | 2 |
| Page Range: | 580-582 |
| Date: | February 2022 |
| Official Publication: | https://doi.org/10.1038/s41375-021-01386-z |
| PubMed: | View item in PubMed |
Repository Staff Only: item control page
